

# Andrew Sulaiman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10787322/publications.pdf>

Version: 2024-02-01

14  
papers

1,318  
citations

1051969

10  
h-index

1181555

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

2772  
citing authors

#	ARTICLE	IF	CITATIONS
1	The entry of nanoparticles into solid tumours. <i>Nature Materials</i> , 2020, 19, 566-575.	13.3	1,036
2	Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states. <i>Molecular Oncology</i> , 2018, 12, 423-440.	2.1	54
3	Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. <i>Oncotarget</i> , 2017, 8, 113269-113281.	0.8	44
4	Co-inhibition of mTORC1, HDAC and ESR1 $\pm$ retards the growth of triple-negative breast cancer and suppresses cancer stem cells. <i>Cell Death and Disease</i> , 2018, 9, 815.	2.7	34
5	CSCs in Breast Cancer – One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs. <i>Cancers</i> , 2019, 11, 1128.	1.7	29
6	Both bulk and cancer stem cell subpopulations in triple-negative breast cancer are susceptible to Wnt, HDAC, and ER $\pm$ coinhibition. <i>FEBS Letters</i> , 2016, 590, 4606-4616.	1.3	28
7	A triple-drug nanotherapy to target breast cancer cells, cancer stem cells, and tumor vasculature. <i>Cell Death and Disease</i> , 2021, 12, 8.	2.7	25
8	Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression. <i>Journal of Biomedical Research</i> , 2018, 32, 81-90.	0.7	22
9	Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1755-1764.	1.9	17
10	Clinically Translatable Approaches of Inhibiting TGF $\beta$ 2 to Target Cancer Stem Cells in TNBC. <i>Biomedicines</i> , 2021, 9, 1386.	1.4	14
11	Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5788.	1.8	11
12	E-cadherin adhesion-mediated Wnt activation for mesoderm specification in human embryonic stem cells needs a soft mattress. <i>Stem Cell Investigation</i> , 2016, 3, 77-77.	1.3	2
13	Nanoparticles Loaded with Wnt and YAP/Mevalonate Inhibitors in Combination with Paclitaxel Stop the Growth of TNBC Patient-Derived Xenografts and Diminish Tumorigenesis. <i>Advanced Therapeutics</i> , 2020, 3, 2000123.	1.6	1
14	At the Intersection of Cardiology and Oncology: TGF $\beta$ 2 as a Clinically Translatable Therapy for TNBC Treatment and as a Major Regulator of Post-Chemotherapy Cardiomyopathy. <i>Cancers</i> , 2022, 14, 1577.	1.7	1